RemeGen Focused on Growing Domestic Business
Shaojing Tong, CFO at Chinese biotech firm RemeGen, discusses the company's first quarter results and shares his confidence in growth in the domestic market. The company's stock has outperformed all of its peers in the MSCI China Healthcare Index since the start of the year. (Source: Bloomberg)
ORIGINAL SOURCE →via Bloomberg Markets
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · CN
- [HEALTH] Who writes the pandemic? State power, individual subjectivity, and the history of the present in China's COVID-19 respon
- [CONFLICT] Sungrow proposes multi-microgrid clusters for mining above 100 MW
- [CONFLICT] Mercedes quarterly profit slumps as China, tariffs weigh
- [ENERGY] China to Allow Higher Fuel Exports in May
- [FINANCE] Volvo Car Earnings Drop on Tougher US, China Competition
- [FINANCE] China targets ‘zombies’ with regulatory headshots to kill off subsidised laggards